title: Allogeneic CAR19 cells clear ALL.
abstract: Chimeric antigen receptor T cells redirected to CD19 (chimeric antigen receptor [CAR19]) show great promise in the clinic to treat refractory CD19+ acute lymphoblastic leukemia (ALL). However, production of autologous CAR19 cells from these patients can be difficult as patients frequently have T-cell dysfunction, due to disease and/or treatment-related effects. In this issue of Blood, Jacoby et al1 addressed this by exploring whether allogeneic donor CAR19 cells could be used to treat ALL-bearing mice using a minor mismatch bone marrow transplant model.
authors.affiliation: PETER MACCALLUM CANCER CENTER.
authors.forename: Paul
authors.initials: P
authors.lastname: Neeson
mesh_terms: D000818:Animals; D018941:Antigens, CD19 / Q000276:immunology*; D006086:Graft vs Host Disease / Q000276:immunology*; D017710:Lymphocyte Transfusion; D009374:Neoplasms, Experimental / Q000276:immunology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology*; D043562:Receptors, G-Protein-Coupled / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D018941:Antigens, CD19; D043562:Receptors, G-Protein-Coupled